ReviewNature reviews. Clinical oncology2014
Immune-based therapies for childhood cancer.
Review in Nature reviews. Clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 86 citations in OpenAlex.
- Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States.Pediatric hematology and oncology · 2017Trial
- Proteomic analysis of Burkitt lymphoma tissues: insights into the impact of age and EBV infection on protein expression and molecular characteristics.Discover oncology · 2025Article
- Pediatric neuro-oncology: Highlights of the last quarter-century.Neoplasia (New York, N.Y.) · 2025Review
- Potential signaling pathways, biomarkers, natural drugs, and chronic myeloid leukemia therapeutics.Frontiers in pharmacology · 2025Review
- Identification of Functional Immune Biomarkers in Breast Cancer Patients.International journal of molecular sciences · 2024Article
- Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions.Frontiers in cell and developmental biology · 2024Review
- The biological role and immunotherapy of gangliosides and GD3 synthase in cancers.Frontiers in cell and developmental biology · 2023Review
- Childhood cancer survival and avoided deaths in Australia, 1983-2016.Paediatric and perinatal epidemiology · 2023Article
- Immunotherapeutic Strategies in the Management of Osteosarcoma.Journal of orthopaedics and sports medicine · 2023Article
- Parent values and preferences underpinning treatment decision-making in poor-prognosis childhood cancer: a scoping review.BMC pediatrics · 2022Article
- Pediatric medulloblastoma express immune checkpoint B7-H3.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- Immunotherapy Associated Neurotoxicity in Pediatric Oncology.Frontiers in oncology · 2022Review
- Role of multidrug resistance-associated proteins in cancer therapeutics: past, present, and future perspectives.Environmental science and pollution research international · 2021Review
- Does lineage plasticity enable escape from CAR-T cell therapy? Lessons from MLL-r leukemia.Experimental hematology · 2021Review
- Review
- Parent values and preferences underpinning treatment decision making in poor prognosis childhood cancer: a scoping review protocol.BMJ open · 2021Article
- A Novel Treatment for Ewing's Sarcoma: Chimeric Antigen Receptor-T Cell Therapy.Frontiers in immunology · 2021Review
- Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy.American journal of translational research · 2021Article
- Diallyl trisulfide regulates cell apoptosis and invasion in human osteosarcoma U2OS cells through regulating PI3K/AKT/GSK3β signaling pathway.Histology and histopathology · 2020Article
- Wilms' Tumor 1 (WT1): The Vaccine for Cancer.Journal of immunotherapy and precision oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
After decades of research, immunotherapies for cancer are demonstrating increasing success. These agents can amplify existent antitumour immunity or induce durable antitumour immune responses in a wide array of cancers. The spectrum of immunotherapeutics is broad, spanning monoclonal antibodies and their derivatives, tumour vaccines, and adoptive therapies using T cells and natural killer cells. Only a small number of immunotherapies have been tested in paediatric cancers, but impressive antitumour effects have already been observed. Mononclonal antibodies targeting GD2 that induce antibody-dependent cell-mediated cytotoxicity improve survival in high-risk neuroblastoma. Bi-specific monoclonal antibodies that simultaneously target CD19 and activate T cells can induce remission in acute B-cell lymphoblastic leukaemia (B-ALL) and adoptive immunotherapy using T cells genetically engineered to express chimeric antigen receptors targeting CD19 induce impressive responses in B-ALL. Efforts are underway to generate and test new immunotherapies in a wider array of paediatric cancers. Major challenges include a need to identify immunotherapy targets on the most lethal childhood cancers, to expand availability of technology-intense platforms, such as adoptive cell therapy, to optimize management of novel toxicities associated with this new class of cancer therapies and to determine how best to incorporate these therapies into standard treatment paradigms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.